A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Prime Medicine, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 50,100 shares of PRME stock, worth $145,290. This represents 0.0% of its overall portfolio holdings.

Number of Shares
50,100
Previous 74,000 32.3%
Holding current value
$145,290
Previous $380,000 49.21%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.41 - $6.7 $130,497 - $256,402
38,269 Added 300.72%
50,995 $197,000
Q2 2024

Aug 14, 2024

SELL
$4.3 - $8.03 $410,529 - $766,640
-95,472 Reduced 88.24%
12,726 $65,000
Q1 2024

May 15, 2024

BUY
$6.35 - $9.39 $687,057 - $1.02 Million
108,198 New
108,198 $757,000
Q3 2023

Nov 14, 2023

BUY
$9.5 - $15.07 $61,978 - $98,316
6,524 New
6,524 $62,000

Others Institutions Holding PRME

About Prime Medicine, Inc.


  • Ticker PRME
  • Shares Outstandng 95,730,200
  • Market Cap $278M
More about PRME
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.